Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 53 positions · Total reported value $2.50B · Top-10 concentration 59.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2024 13F filing, Frazier Life Sciences Management, L.P. disclosed 53 equity positions with a combined reported value of $2.50B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were MIRM ($256.25M), NAMS ($213.40M), PHAT ($182.78M). By sector, the heaviest allocations are Health Care 89.8%, Materials 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+6.5pp) and away from Other (-6.5pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 79% of names.

The largest new positions opened in Q3 2024 were MBX ($155.50M), ASND ($19.91M), ALKS ($16.13M).

Of the 3 positions fully exited versus the prior quarter, the largest were CERE ($16.07M), APLT ($10.68M), ANTX ($4.49M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • MBX MBX BIOSCIENCES INC · $155.50M
  • ASND ASCENDIS PHARMA A/S · $19.91M
  • ALKS ALKERMES PLC · $16.13M
  • ORKA ORUKA THERAPEUTICS INC · $11.70M
  • LXEO LEXEO THERAPEUTICS INC · $11.31M
  • DAWN DAY ONE BIOPHARMACEUTICALS I · $9.61M
  • NUVB NUVATION BIO INC · $2.79M
  • PIRS PIERIS PHARMACEUTICALS INC · $266.87K

Fully Exited (vs previous quarter)

  • CERE CEREVEL THERAPEUTICS HLDNG I · prev qtr: $16.07M
  • APLT APPLIED THERAPEUTICS INC · prev qtr: $10.68M
  • ANTX AN2 THERAPEUTICS INC · prev qtr: $4.49M
  • MGX METAGENOMI THERAPEUTICS INC · prev qtr: $1.00M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 89.8%
Materials 0.1%
Other 10.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.57M $256.25M 10.27%
10.27%
Add
2 12.86M $213.40M 8.55%
8.55%
Add
3 10.11M $182.78M 7.33%
7.33%
Hold
4 988.46K $179.93M 7.21%
7.21%
Hold
5 5.99M $155.50M 6.23%
6.23%
New
6 2.42M $126.62M 5.08%
5.08%
Add
7 879.40K $100.49M 4.03%
4.03%
Reduce
8 3.38M $97.36M 3.90%
3.90%
Add
9 3.76M $95.74M 3.84%
3.84%
Add
10 1.75M $86.23M 3.46%
3.46%
Hold
11 8.79M $81.70M 3.27%
3.27%
Hold
12 2.83M $75.61M 3.03%
3.03%
Reduce
13 2.21M $74.01M 2.97%
2.97%
Add
14 19.39M $52.94M 2.12%
2.12%
Add
15 1.59M $52.21M 2.09%
2.09%
Hold
16 1.04M $46.39M 1.86%
1.86%
Add
17 997.46K $45.23M 1.81%
1.81%
Hold
18 875.67K $44.21M 1.77%
1.77%
Hold
19 3.69M $42.71M 1.71%
1.71%
Hold
20 4.14M $42.46M 1.70%
1.70%
Hold
21 633.72K $35.20M 1.41%
1.41%
Add
22 8.16M $34.59M 1.39%
1.39%
Hold
23 770.00K $29.05M 1.16%
1.16%
Hold
24 1.49M $27.44M 1.10%
1.10%
Reduce
25 7.38M $24.65M 0.99%
0.99%
Hold
26 5.10M $20.95M 0.84%
0.84%
Add
27 1.15M $20.88M 0.84%
0.84%
Hold
28 133.33K $19.91M 0.80%
0.80%
New
29 10.62M $18.69M 0.75%
0.75%
Hold
30 373.10K $18.64M 0.75%
0.75%
Hold
31 731.02K $17.19M 0.69%
0.69%
Reduce
32 4.62M $16.78M 0.67%
0.67%
Hold
33 576.13K $16.13M 0.65%
0.65%
New
34 1.35M $15.46M 0.62%
0.62%
Add
35 477.33K $11.70M 0.47%
0.47%
New
36 1.25M $11.31M 0.45%
0.45%
New
37 1.89M $10.18M 0.41%
0.41%
Add
38 936.58K $10.12M 0.41%
0.41%
Hold
39 3.01M $9.91M 0.40%
0.40%
Hold
40 689.65K $9.61M 0.39%
0.39%
New
41 2.87M $8.03M 0.32%
0.32%
Hold
42 3.06M $7.81M 0.31%
0.31%
Hold
43 1.07M $7.51M 0.30%
0.30%
Hold
44 1.00M $7.40M 0.30%
0.30%
Hold
45 470.34K $7.23M 0.29%
0.29%
Hold
46 285.33K $7.03M 0.28%
0.28%
Hold
47 702.69K $6.01M 0.24%
0.24%
Reduce
48 5.99M $3.60M 0.14%
0.14%
Add
49 500.33K $3.50M 0.14%
0.14%
Hold
50 108.76K $3.39M 0.14%
0.14%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2024-Q3?

In its 2024-Q3 13F filing, Frazier Life Sciences Management, L.P. reported 53 equity positions worth $2.50B in aggregate; its largest disclosed positions were MIRM ($256.25M), NAMS ($213.40M), PHAT ($182.78M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $2.50B of long equity holdings across 53 positions as of 2024-Q3. Top-10 holdings account for 59.9% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →